New FDA approval expands treatment options for chronic spontaneous urticaria patients aged 12 years and older

Findings independent of autoimmune conditions or dupilumab use

Approval granted for adults and children 12 years and older who remain symptomatic despite antihistamine treatment

Unexpected imaging findings seen in 49 percent of imaged tumors, resulting in changed management in 47 percent of cases

Significant reductions seen in end points, including weekly Itch Severity Score, weekly Urticaria Activity Score

Frequent treatment alterations of off-label biologics and nonsteroidal systemic agents observed

ctDNA detection at baseline was associated with worse recurrence-free, overall survival in BRAF^V600-mutant stage III melanoma

Risk for brain metastases development increased in association with elevated plasma levels of S100B, higher metastatic stage

Royal blue backgrounds preferred for photographing darker skin, offering increased contrast without aberrant hues

In this recurring column, Dermsquared and J.P. Morgan provide tailored financial strategies and investment insights for the dermatology community. Each 500-word article highlights key...

Baricitinib efficacious for achieving holistic response across all three hair-bearing sites

Quality of images produced by autonomous TBP and dermoscopic device comparable to standard dermoscopic techniques

All lesions demonstrated improvement by week 24, with 42 percent achieving ≥80 percent repigmentation

Nonbrisk tumor-infiltrating lymphocytes denoted high risk and were present in 80 percent of progressing tumors

Estrogen treatment increased the risk for all investigated skin cancers

Factors include lower income, non-Hispanic White race, Medicaid/uninsured, greater distance to treatment centers

No evidence of different cardiovascular safety profiles seen for ustekinumab versus adalimumab, etanercept, secukinumab

Delgocitinib well tolerated and efficacious when used as needed in 36-week open-label trial 

Risks for local recurrence, nodal metastases, distant metastases, disease-specific death increase as risk factor number increases

Significantly more patients receiving baricitinib 2 mg, 4 mg had SALT score ≤20, ≤10 versus placebo at week 36

Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after treatment-free interval

Agency says 90 percent of tested products have undetectable or extremely low levels of benzene

Memorial Sloan Kettering Cancer Center and Melanoma Institute of Australia models are most frequently externally validated